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Abstract
Purpose: The aim of this study was to develop and characterize a novel peptide imaging agent
for noninvasive near-infrared fluorescence imaging of protein transport by the lymphatics. An
imaging agent consisting of a cyclic albumin-binding domain (cABD) peptide, with sequence,
Arg-Leu-Ile-Glu-Asp-Ile-Cys-Leu-Pro-Arg-Trp-Gly-Cys-Leu-Trp-Glu-Asp-Asp-Lys, was conju-
gated to a near-infrared fluorophore, IRDye800CW, allowing for enhanced vascular uptake,
retention, and fluorescence imaging.
Procedure: Characterization of the cABD-IRDye800 peptide conjugate was performed using
fluorescence spectroscopy to assess optical properties and SDS-PAGE and Biacore binding
assays to determine binding affinity and specificity. Fluorescence imaging of normal C57BL/6
mice was conducted to monitor lymphatic uptake and retention.
Results: cABD-IRDye800 exhibited approximately six times greater fluorescent yield and greater
stability than indocyanine green, an agent previously used in humans to image lymphatic vasculature.
The agent exhibited affinity for albumin with IC50 and Kd in the nanomolar range and demonstrated
superior retention characteristics within mouse lymphatics when compared with IRDye800CW.
Conclusions: cABD-IRDye800 has utility for assessing lymphatic function in mouse models of human
lymphatic disease and the potential for use in clinical diagnostic imaging of the lymphatic vasculature.
Key words: Near-infrared fluorescence, Lymphatic imaging, Albumin peptide conjugate
List of Abbreviations ABD Albumin-binding domain; ANOVA Analysis of variance; AAALAC
Association for Assessment and Accreditation of Laboratory Animal Care; cABD Cyclic albumin-
binding domain; CLAMC Center for Laboratory Animal Medicine and Care; EMCCD Electron-
multiplying charge-coupled device; Fab Antibody binding fragment; HSA Human serum albumin; ICG
Indocyanine green; MSA Mouse serum albumin; NHS-EDC N-Hydroxysuccinimide-N-ethyl-N′-
(dimethylaminopropyl)-carbodiimide; NIR Near infrared; NP Nanoparticle; OVA Ovalbumin; ROI
Region of interest; SA Serum albumin; ScDb Single-chain diabody; SDS-PAGE Sodium dodecyl
sulfate-polyacrilamide gel electrophoresis; SPR Surface plasmon resonance; MW Molecular weight
Introduction
A
lthough the lymphatic system was first described in the
1600s and is recognized to be important to human
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Correspondence to: Eva Sevick-Muraca; e-mail: eva.sevick@uth.tmc.eduhealth [1, 2], much remains to be learned about its structure
and function in both health and disease. Functions of the
lymphatics include immune regulation, protein transport,
and fluid homeostasis, which are carried out by a complex
network of vessels. The network begins with the initial
lymphatic capillaries found in the dermis that drain into
larger lymphatic vessels which in turn, propel lymph to
lymph nodes through the action of lymphangions, and ends
at the subclavian vein where lymph is returned to the blood
circulation. Failure of lymphatic vessels to function properly
due to a genetic defect, injury, or drug interaction may lead
to swelling and edema, that if not resolved, leads to
lymphedema, a condition in which fluid retention in the
extremities causes chronic edema and pain. Eventual fibrosis
of the affected tissue may occur owing in part to the lack of
lymphatic protein transport from interstitial tissues.
Human genetic studies have, thus far, revealed three
genes linked to congenital lymphedema: VEGFR3 [3, 4],
SOX18 [5], and FOXC2 [6]. Animal studies with condi-
tional and total knockout of these and other genes [7–10]
have shown they are important for early development,
establishment, and maintenance of the lymphatic system.
More recent work shows that acquired forms of lymphe-
dema, such as that following cancer nodal staging surgeries,
may also be associated with gene susceptibility in humans
[11]. In addition, one of the most common off-target effects
of marketed and investigational therapeutics is the edema
that can occur due to the decreased transport capacity of the
lymphatics, enhanced capillary filtration of the blood
vasculature, or a combination of both.
Unfortunately, the lymphatic architecture and function
in both humans and mouse models of disease has not
been well characterized due to the lack of in vivo imaging
techniques with sufficient temporal and spatial resolution
and with adequate contrast agents (for review, see Ref.
[12]). Currently, the clinical gold standard for lymphatic
imaging is lymphoscintigraphy which consists of an
intradermal or subcutaneous injection of a radiocolloid
contrast agent, typically 99mTc, followed by imaging with
a gamma camera. The injection can be painful; imaging is
time consuming requiring several minutes to acquire
images; the procedure exposes the patient to ionizing
radiation; and the images exhibit poor spatial and
temporal resolution [13, 14]. Due to these limitations,
other imaging methods including computed tomography
[15, 16] and magnetic resonance [17] have been inves-
tigated for enhanced sensitivity imaging of the lymphatics.
Unfortunately, they require potentially painful and dam-
aging cannulation of lymphatic vessels, large amounts of
contrast agent, and extensive imaging equipment and
instrumentation. Recently, our research team and others
(for review, see Ref. [18]) have demonstrated clinical,
noninvasive, near-infrared (NIR) fluorescence imaging of
human lymphatics using the tricarbocynanine dye, indoc-
yanine green (ICG), and comparatively compact NIR
imaging instrumentation. NIR fluorescence with excitation
at 9750 nm is advantageous for deep tissue imaging
owing to a high signal-to-noise ratio, minimal light
absorption, maximal tissue penetration, and low back-
ground due to minimal autofluorescence. ICG has max-
imal absorption at ~780 nm and is approved for clinical
use in vascular and hepatic function testing on the basis
of its dark green color [19] and its ability to associate
with albumin [20]. Upon properly designing instrumenta-
tion for sensitive collection of its fluorescence, we have
performed investigational human lymphatic imaging with
rapid image acquisition (200–800 ms) under conditions of
ICG microdosing after intradermal injections of as little as
25 μg[ 21–26]. Furthermore, lymphatic phenotyping of
disease on the basis of vessel architecture and function
has also been demonstrated using this method [25].
Although ICG is retained in the lymphatics due to its
association with serum proteins, it is an unstable fluorophore
requiring its use within hours of reconstitution in saline. A
detailed study of degradation kinetics showed that under
aqueous conditions, ICG degrades with first-order kinetics.
Under the most favorable conditions of darkness and at low
temperature (8°C), the half life of ICG was approximately
20 h [27]. Exposure to light and increased temperature
further accelerated the degradation of ICG. The intensity and
wavelength of light also significantly impacted the degrada-
tion time. Interestingly, ICG exposure to light at 786 nm,
(which is the wavelength used by our camera systems),
caused faster degradation and a minimal half life of only
2.3 h [27]. An additional HPLC degradation study of ICG in
saline showed that by 25 h a 100 μg/mL solution of ICG had
a 70% degradation peak with only 30% of the ICG peak
remaining (Electronic Supplementary Materials). The rapid
appearance of degradation products makes ICG less favor-
able as a clinically acceptable fluorophore than newly
available, more stable fluorophores. These alterations of
the fluorescent properties of ICG result in a dim signal, and
impair the visualization of deep lymphatic structures such as
the saphenous lymphatic channel of the lower leg. Increasing
the concentration of ICG leads to a gradual decline in
fluorescence intensity [27], which arises due to stacking of
dye molecules and resultant quenching which has been
described previously [28, 29].
Herein, we present our work to develop a brighter, but
low molecular weight NIR fluorescent conjugate that is
capable of deep tissue lymphatic imaging while also
associating with plasma proteins for retention within
vascular spaces. The use of plasma proteins such as
albumin has recently become a popular strategy for
improving the pharmacokinetics and decreasing the clear-
ance of therapeutics targeted to a variety of diseases
including arthritis [30], HIV [31] ,a n dm a n yt y p e so f
cancer [32–36]. These strategies often take advantage of
the fact that due to increased metabolic activity and
enhanced permeability of the blood vasculature of tumors
and inflammatory tissue, there is an increased uptake and
accumulation of serum proteins in these tissues. Further-
302 C.A. Davies-Venn et al.: Protein Sequestering Lymphatic Imaging Agentmore, a lack or impairment of lymphatic vasculature
around the tumor may cause a further increase of protein.
Application of albumin binding strategies has shown
efficacy in vitro and also in several animal models, for
summary see Table 1 [37–50]. Half-life extension meth-
ods have included the development of a maleimide
derivative of doxorubicin conjugated to albumin, which
covalently binds to the free thiol group of cysteine-34 on
the albumin protein. As cysteine-34 is unique to albumin,
this protein marker provides a general strategy for
increasing retention time of therapeutic conjugates of
maleimide derivatives by their direct binding to endoge-
nous albumin [37]. While the endogenous albumin
strategy is primarily useful for maleimides, after inves-
tigating several half-life extension strategies including
pegylation, N-glycosylation, and HSA fusion, Linhult
and Johansson [38, 39], identified an albumin-binding
domain (ABD) from the bacterial protein Streptococcal G
that was able to bind with nanomolar to fentomolar
affinity for albumin. They conjugated this ABD to
antibody fragments including a Fab and single-chain
diabody (scDb). The scDb-ABD was found to have a
10-fold increased half life and higher accumulation in
CEA-positive tumors and be favorable for tumor therapy
while significantly reducing molecular weight compared
with direct antibody fusion methods. In a related
approach, in 2002 Dennis et al. [40] used phage display
to isolate several peptides that bound with high affinity to
serum albumin of multiple species and which could
potentially be conjugated to a variety of ligands using N-
hydroxysuccinimide (NHS) ester chemistry. Mutational
analysis and binding studies showed that several serum
albumin (SA) peptides were capable of binding with
nanomolar affinity and upon conjugation to a Fab fragment
were able to extend plasma half-life 25–58-fold thereby
increasing therapeutic efficacy. Specifically, one peptide,
SA21 showed a high affinity for albumin at a site distinct
from albumin’s other important ligand binding sites and
stability in serum while also maintaining the ability of the
Fab to bind tissue factor in vivo. Thus, this approach
provides a novel method of association to albumin that can
be useful for enhancing vascular retention.
We have employed a cyclic version of SA21, and we
term the cyclic albumin-binding domain (cABD) peptide.
We have conjugated the stable, cABD peptide, with a
bright NIR fluorophore, IRDye800CW, which itself has
favorable clearance, safety, and toxicity profiles [51]. The
chemical structure of cABD-IRDye800 is shown in
Fig. 1. We have also characterized and demonstrated
the superiority of cABD-IRDye800 compared with ICG
in studies of mouse lymphatics. The use of cABD-
IRDye800 as a NIR imaging agent will enable a better
understanding of lymphatic vasculature, help elucidate
the pathophysiology of lymphatic disease, and provide
insight into other diseases in which the lymphatic system
m a yp l a yar o l e .
Materials and Methods
Agent Preparation
ICG was obtained from Akorn (Lake Forest, IL), stored at room
temperature and reconstituted in sterile phosphate-buffered saline
(PBS) immediately prior to use. IRDye
®800CW NHS ester was
purchased from LI-COR Biosciences (Lincoln, NE) and recon-
stituted in PBS or dimethyl sulfoxide (DMSO) prior to use. The
cABD peptide, RLIEDICLPRWGCLWEDDK, with disulfide
bond between Cys7 and Cys13, 995% purity, was obtained
from Bachem (Torrance, CA), stored as received at −20°C, and
reconstituted immediately before use in Sorenson’sp h o s p h a t e
buffer (pH 8–8.5). cABD peptide conjugation to IRDye800 was
performed by combining equimolar amounts of IRDye800 in
DMSO and cABD peptide in phosphate buffer. The specific
conjugation reaction occurs by formation of a stable amide bond
between the free amine on the terminal lysine of the cABD
peptide and the NHS ester reactive group on IRDye800.
Although it may appear there are two potential reactive sites
on the peptide: (1) the terminal lysine and (2) the terminal NH2
group; the terminal NH2 on the peptide is an amide, and is
therefore, unreactive (Fig. 1). Conjugation occurred overnight at
4°C on a rotator platform under dark conditions. The conjugated
cABD peptide was successfully purified using a semi-prep
HPLC system equipped with a Zorbax column (C-18, 250×
10 mm) using a mobile phase of 0.1% TFA in H2O/0.1% TFA
in CH3CN gradient and flow rate of 1 mL/min. A retention time
of 32.3 min was measured using EzChrome Elite software. The
conjugate was then dried using a vacuum evaporator (Thermo
Scientific Inc.) to remove water and residual TFA and stored at
−20°C protected from light.
Characterization of Fluorophores
Fluorescence optical properties of the fluorophores were deter-
mined using the Fluorolog Tau-3 Spectrofluorometer (Horiba
Jobin Yvon, Edison, NJ) and absorbance was recorded using the
DU-800 Spectrophotometer (Beckman Coulter, Brea CA). All
measurements were taken at fluorophore concentrations ≤1 μM.
At this low concentration, confounding effects such as quench-
ing of ICG are avoided and fluorophores are more easily
compared. In addition, each fluorophore was purified by
lyophilization to remove TFA or solvent, prior to being
measured to the nearest microgram and prepared at the desired
concentration by dilution in the appropriate solvent. Molecular
weights (MW) for ICG and IRDye800 were confirmed by the
respective vendors and cABD-IRDye800 MW was confirmed by
mass spectrometry. Consistency in the preparation methods for
each fluorophore also helped ensure accuracy in the final
concentration of each fluorophore used to record optical proper-
ties and in the event of any minor solvent or salt effects, these
would be similar among all fluorophores. Excitation and
emission spectra of 1 μM solutions of ICG, IRDye800 and
cABD-IRDye800 were obtained at wavelengths of 785 and
830 nm respectively, with an integration time of 0.3 s.
Extinction coefficients were determined from the slope of
absorbance at 785 nm as a function of the concentration of
serial dilutions of each agent at concentrations of 0.01, 0.1, 0.5,
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304 C.A. Davies-Venn et al.: Protein Sequestering Lymphatic Imaging Agentand 1 μM. Fluorescence quantum yield was determined by the
comparativemethod of Williamsetal.[52] using the quantum yieldof
ICG (in water) at 785/830 nm [53] as a reference standard in which
fluorescence of each fluorophore at the above-mentioned concen-
trations was plotted as a function of absorbance. The gradient of this
plot and that of the ICG reference standard was then used to calculate
quantum yield using Williams’ equation [52]. Frequency domain
lifetime measurements were acquired using 1 μM concentrations
of each fluorophore over ten frequencies between 20 and
200 MHz, with an excitation and emission of 785 and 830 nm,
respectively, and integration time of 12 s. ICG, with known
lifetime 0.56 ns [53] was used as a reference standard.
Mass spectrometry was performed by the Mass Spectrometry
Laboratory in the Pharmaceutical Development Center of the
Department of Experimental Therapeutics at the University of
Texas MD Anderson Cancer Center in Houston TX. The
lyophilized cABD-IRDye800 conjugate was dissolved in 80:20
methanol/0.2% formic acid aqueous (pH 3.0) at a concentration of
1 μg/mL. This solution was directly infused into a Waters Quattro
ZQ single quadrupole mass spectrometer, operated in electrospray-
positive ionization and full scan mode. The confirmation of the
molecular weight was done by application of deconvolution
software, Waters MaxEnt 3.
An HPLC stability study was performed over 15 days under
four storage conditions: water at room temperature or 4°C and
PBS at room temperature or 4°C. Stability was assessed by an
analytical HPLC system equipped with a Hitachi LaChrom Ultra
column (C-18, 5 μm, 4.6×150 mm) using a mobile phase of
0.1% TFA in H2O/0.1% TFA in CH3CN gradient and flow rate
of 1 mL/min over 60 min. The percent area of the conjugate
peak at a retention time of 24.9 min, Fig. 2,w a su s e dt o
determine the purity and stability of the cyclic conjugate.
S t a b i l i t yw a sm e a s u r e da td a y0 ,1 ,2 ,3 ,4 ,7 ,a n d1 5 .
The IC50 of cABD-IRDye800 was determined using a
competitive binding assay modified from Dennis et al. [40].
Briefly, Maxisorp fluorescent plates (Nunc, Rochester, NY) were
coated with mouse serum albumin (Sigma, St Louis, MO) and
incubated overnight at 4°C. Plates were washed with PBS+
0.05% Tween20 (Sigma, St. Louis, MO) to remove unbound
albumin and were then blocked with TBS in casein (Pierce,
Rockford, IL) for 1 h at 25°C. Equimolar amounts of uncon-
jugated peptide and peptide conjugate were combined in
centrifuge tubes for five different concentrations (0–50 nM) of
cABD peptide. The resulting peptide solution was then plated on
the albumin coated plate, covered, and incubated for 1–2ha t
room temperature. The plate was washed with PBS with 0.05%
Tween20 to remove unbound peptide, followed by fluorescence
imaging at 800 nm on an Odyssey
® Infrared Imager (LI-COR
®
Biosciences, Lincoln, NE). The average and standard deviation
of four IC50 values were determined.
Affinity measurements were obtained via SPR using a BIA-
CORE T100 (GE Healthcare) instrument similar to a work
Fig. 1. A chemical structure diagram showing cABD-IRDye800 including the specific site of conjugation and formation of an
amide bond between the free amine in the terminal lysine side chain of the cABD peptide and the NHS ester reactive site of
IRDye800 CW. The S–S, disulfide bond was added to stabilize the peptide and maintain uniform product once conjugated to
IRDye800.
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MSA to a CM5 chip using standard NHS-EDC chemistry. A
reference flow cell was inactivated for in-line subtraction. Kinetic
analysis was performed at 25°C in HEPES-buffered saline EP+
buffer (GE Healthcare) at a flow rate of 60 μl/min. Five 2-fold
dilutions of each peptide beginning at 500 nM were analyzed in
duplicate, injected over the flow cells for 1 min and dissociation
monitored for 5 min. The surface was regenerated with glycine 3.0
and allowed to stabilize 30 s prior to subsequent injections. BIA
evaluation software was used to determine Kd using a 1:1 binding
model. Affinities provided were the average of three independent
experiments for each peptide dilution series with standard deviation
recorded.
To confirm binding specificity of the conjugate, a 0.2 mg/mL
solution of cyclic peptide was incubated with an equimolar
concentration of MSA or ovalbumin (OVA) or 5% human serum
for 1 h at room temperature. The cyclic peptide conjugate, MSA,
OVA, and free IRDye800 were separated using sodium dodecyl
sulfate-polyacrilamide gel electrophoresis (SDS-PAGE). Pre-cast
4–20% long life gels (NuSep, Lawrenceville GA), were run using
1× Tris/Hepes/SDS running buffer for 1–1.5 h at 100 V, followed
by fluorescence imaging at 800 nm on an Odyssey NIR imager, at
an intensity of 1.5 and focus offset of 3 mm. Gels were then stained
with Biosafe Coomassie Blue (BioRad, Hercules CA) overnight at
4°C, to elucidate protein bands, and imaged using an Alpha
Innotech gel imaging system (Cell Biosciences, Santa Clara CA).
Similarly, to assess albumin binding of ICG and IRDye800,
equimolar amounts of ICG and IRDye800, were each incubated
with 0.2 mg/mL MSA or 5% human serum. SDS-PAGE was
performed as described above, followed by fluorescence imaging at
800 nm using the Odyssey NIR imager. Gels were stained with
coomassie blue overnight at 4°C, to elucidate protein bands, and
imaged using the Alpha Innotech gel imaging system.
Measurement of Partition Coefficients
The lipophilicity of cABD-IRDye800 was assessed by determi-
nation of the water-octanol partition coefficient. 1-Octanol (1 mL)
was added to a solution of approximately 40–50 μg of cABD-
IRDye800 in water (1 mL), and the layers were vigorously
vortexed for 5 min at room temperature and again mixed after 2 h
for 3 min. The tubes were centrifuged at 14,000 rpm for 5 min.
Three samples of each layer were analyzed spectrophotometrically
using the DU-800 Spectrophotometer (Beckman Coulter, Brea
CA), applying this formula:
Pconc: mg=mL ðÞ ¼ A280   0:03   A780 ðÞ ="P ðÞ   MWP;
P ¼ ICG;IRDye800 and cABD   IRDye800 ðÞ
where MW is the molecular weight, ε is the extinction
coefficient, and A is absorption.
The partition coefficient was determined by calculating the ratio
of concentration in octanol/concentration in water and expressed as
LogP. At least three independent experiments were performed in
triplicate to give the mean LogP value.
Fig. 2. HPLC chromatogram showing the cABD-IRDye800 peptide conjugate peak that was eluted from a Zorbax semi-prep
C-18A column at 25 min with 95% purity. The unconjugated (free) peptide and cABD-IRDye800 conjugate can be seen as
separate peaks in the 280 nm channel.
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All animal studies were approved by the University of Texas
Health Science Center Houston, Center for Laboratory Animal
Medicine and Care (CLAMC) animal welfare committee. Mice
were housed in the university’s AAALAC accredited facilities
under sterile conditions according to CLAMC policy. Animal
studies were conducted using shaved 6–7-week-old female,
C57BL/6 mice (Harlan, Charles River). Mice were divided into
experimental groups, anesthetized with isofluorane inhalation, 2–
3% until unresponsive to painful stimuli and placed on a heating
pad to maintain body temperature at 37° during each imaging
session (~30 min/animal). Mice were closely monitored during and
after imaging for any adverse events, of which there were none.
Each mouse was injected intradermally at the base of the tail with
20 μL of 500 μM ICG, or 20 μL of 100 μM cABD-IRDye800, in
order to assess the performance of each fluorophore in vivo. The
injections were all made by the same investigator (C. D-V) and the
injection site was covered with sterile tape immediately prior to
imaging to block injection site fluorescence and prevent camera
saturation. Figure 3 is a fluorescent image superimposed on a
white-light image showing a typical view of normal murine
lymphatic vasculature after injection of NIR fluorophore cABD-
IRDye800 at the base of the mouse tail. Labels are included to
orient the reader and highlight pertinent parameters including,
injection site, a lymphatic vessel and inguinal lymph node. Animals
were illuminated by a laser diode (100 mA and 80 mW for 785 nm,
Sanyo; Richmond, IN) with the light source expanded to a uniform
circular area approximately 8 cm in diameter. Fluorescence
emission was collected using an EMCCD camera with a holo-
graphic notch-plus band-rejection filter (785-nm center wavelength
for ICG) and a bandpass filter (830-nm center wavelength for ICG)
placed prior to the lens to reject backscattered and reflected
excitation light. Fluorescence images were acquired with an
integration time of 200 ms. For registration purposes, “white-light”
images were taken by removing the filters and acquiring images
over 500-ms integration time. Up to 750 fluorescent images and
three white-light images were acquired immediately after injection
on the left and right side of each animal. Statistical analyses of
differences in fluorescent intensity between the agents at each time
point were assessed by analysis of variance (ANOVA) and
Student’s t test in which α=0.05.
Lymphatic Clearance
C57/Bl6 mice were anesthetized using 2–3% isoflurane during the
induction phase and minimal G1% isoflurane during the duration of
the experiment which lasted 50 min. Mice were maintained at 37°
using a heating pad or lamp. Anesthetized mice were intradermally
injected with ICG (n=5), IRDye800 (n=4), and cABD-IRDye800,
(n=3), using a 31-gauge needle. To quantify lymphatic clearance of
each agent, the fluorescence intensity within the region near the
inguinal lymph node was recorded at five time points: 0.5, 2.5, 15,
30, and 50 min after injection of each NIR agent. To account for
differences in fluorescent intensity, 20 μL of 500 μM ICG or 20 μL
of 100 μM of IRDye800 and cABD-IRDye800 were administered
to each mouse and fluorescence images (200 ms/frame), were
acquired immediately afterward and at each successive time point
using the camera system described above. Seven hundred fifty
images were taken for the first time point and 200 images for each
successive time point. Images were processed using V++ software
(Digital Optics; Auckland, New Zealand), and data were analyzed
to determine in vivo fluorescent intensities in select ROI using
ImageJ (NIH, Bethesda, MD) and Matlab (The Mathworks).
Fluorescence was normalized to the maximum fluorescence
intensity within the inguinal lymph node for each agent and plotted
as a function of time. Statistical analysis of the data were conducted
using a Student’s t test with α=0.05.
Results
Characterization of Imaging Agents
Table 2 lists the MW, extinction coefficient at 785 nm,
quantum yield at 785/830 (Ex/Em), and lifetime for ICG,
IRDye800CW, cABD-IRDye800 at 785/830 (Ex/Em). In
addition, Table 2 also lists the brightness of IRDye800 and
cABD-IRDye800 relative to ICG which was computed by
taking the ratio of ((extinction coefficient)×(quantum yield))/
(extinction coefficient of ICG)×(quantum yield of ICG)). The
results showed that IRDye800 itself was approximately five
times brighter than ICG, and that on a molar basis the
IRDye800 conjugate retained its brightness over ICG. cABD-
IRDye800 was 5.6 times brighter and had 1.6 times longer
lifetime than ICG. In addition, the lifetime of IRDye800 and
cABD-IRDye800 were similar to one another, indicating
Fig. 3. An example of normal murine lymphatic vasculature
as typically seen after injection of 20 μL of 200 μM cABD-
IRDye800 at the base of the tail, a near-infrared fluorescence
image is overlaid on a white-light image to aid in reader
orientation, pertinent parameters including injection site,
lymph vessel, and inguinal lymph node are denoted.
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the cABD peptide.
Mass spectrometry confirmed that the deconvoluted
molecular weight of the cABD-IRDye800 conjugate was
3,401 Da which was in agreement with the expected
molecular weight of 3,404 Da based on the sum of the
known molecular weights of the cABD peptide and
IRDye800. A subsequent HPLC stability study showed that
the cABD peptide conjugate remained stable in PBS or water,
at both room temperature and 4°C, through day 15 post-
conjugation. Percent purity of the conjugate immediately after
HPLC purification, for each storage condition ranged between
peak areas of 92–98%. The conjugate peaks were maintained
within a few percent of this initial area over the study period
with the exception of water at room temperature for which
one sample had a slightly decreased peak area of about 75%.
Affinity for Serum Protein
The affinity of the conjugate for albumin was tested by
comparing its IC50 and Kd for MSA to that reported by Dennis
et al. for the peptide alone [40]. We found the purified cyclic
peptide conjugate had an IC50 of 44.83±4.85 nM. Kd was
assessed by surface plasmon resonance and the Kd of the
unconjugatedcABDpeptidewasfoundtobe65±10nM.While
measuring the Kd of cABD-IRDye800, interference between
the 760 nm light source of the BIAcore and the peak excitation
wavelengthofIRDye800(~774nm),possiblycausedarecently
described phenomenon known as surface plasmon-coupled
emission resonance [54], which inverted the time response
curve,andtheKdcouldnotbedetermined.Therefore,theKdof
cABD conjugated to Dylight680, a spectrally and structurally
similar near-infrared dye, was used to confirm conjugate
binding to MSA. The Kd of cABD-Dylight680 was 32±
5 nM. The sensograms of cABD-Dylight680 and cABD-
IRDye800 showed a similar pattern of binding indicating a
constant angle of refraction with only changes due to reduction
of signal intensity due to absorbance by the fluorophore.
Sodium Dodecyl Sulfate-Polyacrilamide Gel
Electrophoresis
Binding specificity of peptide conjugate was assessed using
SDS-PAGE. MSA was the positive control for peptide
binding, while ovalbumin, a structurally distinct form of
albumin was used as a negative control. The NIR fluo-
rescence image in Fig. 4a shows that a fluorescent band was
found only in the samples in which MSA or human serum
(but not OVA) was incubated with cABD-IRDye800. This
fluorescent band migrated to ~70 kD, which is the
approximate molecular weight of cABD-IRDye800 bound
to albumin, thus confirming binding. Figure 4b is the
corresponding coomassie protein stained image of the gel
which shows, the conjugate bound to MSA (70 kD), MSA
(67 kD), and OVA (48 kD), at their expected molecular
weights and shows the bands of the human serum proteins as
well. The result that the cABD conjugate bound to MSA but
did not bind to ovalbumin confirms the specificity of the
interaction between the cABD peptide conjugate and MSA.
Furthermore, the albumin binding capabilities of ICG and
IRDye800 were assessed by incubating both fluorophores in
MSA or 10% human serum. ICG showed binding in both
MSA, as was seen by the ~68 kD fluorescent band in Fig. 5a,
and serum solution; while IRDye800 appeared to bind to MSA
but not human serum. This result suggests that IRDye800 may
be binding too weakly to be detected in human serum. The
corresponding protein image is shown in Fig. 5b.
Partition Coefficients
In order to assess possible differences in hydrophobicity
that may impact binding to albumin, the partition coef-
ficients of ICG, IRDye800 and cABD-IRDye800 as
determined from the ratio of each fluorophores’ concen-
tration in octanol and water were measured and expressed
as LogP values. There was a small but significant differ-
ence (pG0.05 by ANOVA), in the LogP values between
the fluorophores, with IRDye800 having the smallest
LogP, −1.13+/−0.08 indicating the greatest concentration
of fluorophore in the aqueous phase followed by ICG,
−0.69+/−0.03 and then cABD-IRDye800, −0.53+/−0.005.
In Vivo Lymphatic Imaging Studies
Figure 6 shows NIR fluorescence images of the dorsal lateral
side of mice injected with 20 μL of (a) 500 μM ICG or (b)
100 μM of cABD-IRDye800. Similarly to ICG, the peptide
conjugate was visible in the lower trunk region as well as the
Table 2. Table of optical properties for NIR fluorophores
Agent MW Extinction coefficient
a (M cm)
−1 Quantum yield
b Lifetime
b (ns) Relative brightness vs. ICG
ICG 775 103,502±1.1E4 0.016
c 0.56
c 1
IRDye800 1,166 178,378±7.1E2 0.046±3.12E−4 0.93±0.075 4.9
cABD-IRDye800 3,401 171,025±1.4E4 0.054±9.28E−4 0.92±0.102 5.6
aAbsorbance, λ=785 nm
bExcitation/emission, λ=785/830 nm
cSee Ref. [53]
308 C.A. Davies-Venn et al.: Protein Sequestering Lymphatic Imaging Agentinguinal lymph node and the collecting lymphatic vessels
leading up to the axillary lymph node. These results indicate
the conjugate is able to be taken up, traffic through the
lymphatic vasculature and discern key lymphatic features at
concentrations lower than that of ICG.
Lymphatic Clearance Study
The lymphatic clearance of ICG, IRDye800, and cABD-
IRDye800 from the inguinal lymph node was investigated
by measuring the fluorescence intensities within the node at
given intervals between 0 and 50 min. Fluorescent intensities
for each fluorophore were normalized to the maximal
fluorescence intensity due to variations in absolute fluores-
cent counts measured within each region of interest
surrounding the inguinal lymph node. An assessment of
the percent of the maximal total fluorescence at each time
point not only provided a measure of the clearance rate of
the dye from the lymphatics, but also showed the relative
rate of fluorophore entry and exit from the node. cABD-
IRDye800 entered the node more rapidly, as by 2.5 min the
fluorophore had already reached its maximal fluorescence
while ICG did not reach maximum until 15 min. Conversely,
Fig. 5. SDS-PAGE shows a fluorescence and b protein images of ICG and IRDye800 after incubation with MSA and human
serum, showing ICG binds to both, while IRDye800 may only bind MSA.
Fig. 4. SDS-PAGE shows a fluorescence and b protein images of cABD-IRDye800 after incubation with MSA or OVA, showing
specificity of the conjugate for MSA.
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IRDye800 retained at least 80% of the maximal fluorescence
intensity over the study period. (Normalization is necessary
because ICG is a dimmer fluorophore than IRDye800, and
thus a higher concentration, 500 μM (as determined from
prior dose escalation studies) is used to visualize the lymph
node. This increased fluorescence changes the fluorescent
intensity as measured by ImageJ software. Thus, one cannot
meaningfully compare the individual fluorescent intensities
between each agent. Furthermore, the specific fluorescent
intensities would not be able to be replicated by another user
as they are specific to our unique instrumentation.) As the
fluorophore cleared from the node there was an expected
decrease in fluorescence intensity over time. Figure 7 shows
comparisons of the lymphatic clearance of (a) ICG vs.
IRDye800, (b) cABD-IRDye800 vs. IRDye800, and (c) ICG
vs. cABD-IRDye800. ICG had a trend of higher fluores-
cence intensities than IRDye800 at 15, 30, and 50 min,
although only the 30 min time point reached significance
while cABD-IRDye800 showed significantly higher fluo-
rescence than IRDye800 at 30 and 50 min. ICG showed a
trend similar to that of cABD-IRDye800 but did not reach
significance. Statistics were performed using ANOVA and
Student’s t test with α=0.05. The time points in this study
were selected to determine initial baseline clearance data
during an imaging session of approximately 50 min–1h ,
as is typical in human clinical trials. In the preclinical
studies, the ~1 h time frame allowed the anesthesia to be
maintained at a low level over the study period as
opposed to awakening and re-anesthetizing the animals.
As it is clear from the communicated studies that
IRDye800 has a statistically significantly faster clearance
than the other agents, the purpose of the study was met
within this time frame. Additional lymphatic clearance
studies and in vivo whole body clearance and pharmaco-
kinetics over longer time points may be addressed in
further studies.
Discussion
Due to its fluorescent properties, ICG has the ability to
provide fluorescence contrast for vascular imaging. How-
ever, its low quantum efficiency and instability in solution
[55] make ICG a poor fluorophore. Its chemical structure
also limits its ability to be conjugated to targeting moieties.
Consequently, other imaging agents including red excitable
dyes such as Cy 5.5, and probe systems such as quantum
dots have been pursued for imaging purposes, however,
these agents may be limited by reduced tissue penetration,
rapid vascular clearance, and/or questions on uncertain fate
and toxicity. Herein, we have described the optical proper-
ties of cABD-IRDye800, a novel NIR peptide conjugate and
its application in preclinical murine lymphatic imaging. In
vitro studies confirmed the higher extinction coefficient and
quantum efficiency of the IRDye800 conjugate as compared
with ICG, thus showing the enhanced absorptive and
fluorescence capacity provided by IRDye800. Unlike the
findings of other studies [56], we did not find that the
extinction coefficient or quantum yield of 1 μMI C G
solution increased with the addition of albumin, although it
is well known that at higher solution concentrations, ICG
self-quenches and the addition of albumin or aspartic acid
[57] can improve fluorescent yield of ICG. In addition,
cABD-IRDye800 was found to be significantly more stable
than ICG and maintained integrity through a 15-day study
period in water and PBS at room temperature and 4°C.
These results are in sharp contrast to ICG which begins to
degrade within hours and at ambient temperature under
normal light has a half life of only 14 h [27]. More
importantly at the clinically relevant excitation wavelength
Fig. 6. Comparative near-infrared fluorescence imaging of normal C57Bl/6 mice injected at the base of the tail with 20 μLo fa
500 μM ICG or b 100 μM cABD-IRDye800, showing visualization of the initial superficial lymphatic vasculature, the inguinal
lymph node and a conducting lymphatic vessel leading from the inguinal to axillary node. Imaging reveals ability of the peptide
conjugate to provide comparable imaging quality at a lower dose than ICG.
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thereby further reducing its useful lifetime. As such the
brighter and more stable cABD-IRDye800 provides an
opportunity to improve upon these limitations. For further
characterization of the peptide conjugate, binding assays
with MSA were performed and showed that upon conjuga-
tion to IRDye800, the cABD peptide was able to maintain its
specificity and affinity for albumin, thus confirming that the
addition of the fluorophore did not significantly alter the
binding properties of the peptide. The IC50 of cABD-
IRDye800 for MSA was found to compare favorably to the
unlabeled cABD peptide as described by Dennis et al. [40].
In addition, the Kd of cABD-Dylight680 was in the
nanomolar range again showing a high affinity of the
conjugate for MSA, and consistency of the peptide once
conjugated to a fluorophore. Although albumin-binding
domain conjugates with higher binding affinity for albumin
have been described [45, 50], a recent study has shown that
increasing affinity beyond the nanomolar range has only
minimal effects on increasing half life and that half-life
extension by ABD is only weakly influenced by affinity for
albumin or valency [47]. As such, we have selected the
peptide conjugate that provides the optimal combination of
favorable properties for binding to albumin, allowing for its
retention in the lymphatics, as well as for in vivo lymphatic
imaging.
The ability of the conjugate to bind albumin and serum
proteins is significant because it allows for the imaging of
protein movement from the tissue space into the lymphatics.
This is relevant to the present study because while the blood
circulation is capable of taking up fluid and small proteins,
large proteins and macromolecules can only be taken up by
the large openings in the lymphatic capillaries. Therefore,
when the peptide conjugate associates with these large
serum proteins, it is preferentially taken up by the
lymphatics. The protein association could be especially
useful in monitoring diseases such as lymphedema in which
impaired lymphatic flow causes an accumulation of protein
in the interstitial space followed by a rise in oncotic pressure
and the consequent buildup of excess fluid in the tissue,
causing edema. Thus, the conjugate affords us the unique
opportunity to study a key aspect of the development of
edema and to assess the role of protein movement in the
progression of lymphatic disease.
Although ICG is also known to associate with serum
proteins, it is difficult to find direct experimental evidence
Fig. 7. Lymphatic Clearance Study: C57Bl/6 mice were injected at the base of the tail with 20 μL of 500 μM ICG or 100 μM
IRDye800 or cABD-IRDye800 and imaged over several time points between 0 and 50 min to determine retention of
fluorophores within the inguinal lymph node. Clearance from the node was compared between a ICG and IRDye800, b cABD-
IRDye800 and IRDye800, and c ICG vs. cABD-IRDye800.
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comparing the serum binding properties of both ICG and
IRDye800. We found that as expected, ICG associates with
both MSA and human serum showing similar results to that
of cABD-IRDye800. Despite this finding, ICG has signifi-
cant limitations which include its poor optical properties and
instability in solution. Also of considerable importance for
use in lymphatic imaging is the ability of the fluorophore to
provide bright signal imaging when injected in microdose
quantities. This has significant implications for the recon-
stitution and use of ICG in a clinical setting to discern the
presence of lymphatics. In fact, when directly comparing the
stability and fluorescence of ICG and IRDye800, the latter is
clearly superior and serves as a good alternative to ICG.
However, clearance studies show that IRDye800 rapidly
clears from the lymphatics, likely due to a reduced
association to serum proteins. Therefore, we have selected
the cABD-IRDye800 conjugate which allows us to max-
imize fluorescent yield and enhance lymphatic retention.
Interestingly, although IRDye800 did appear to associate
with MSA, it did not appear to bind to human serum even
though the molar concentrations and conditions for incuba-
tion were the same for ICG and IRDye800. These results
indicate that IRDye800 may have a reduced affinity for or
inability to bind human serum proteins and therefore may
not be useful for imaging protein movement in clinical
lymphatic studies.
To assess another factor that may impact binding to
albumin, the partition coefficient of each fluorophore in
octanol and water was measured, which provided an order of
hydrophobicity for the fluorophores as cABD-IRDye8009
ICG9IRDye800. These results suggest that the slightly
increased hydrophobicity of ICG and cABD-IRDye800
may favor their binding within the hydrophobic albumin
binding pocket as compared with IRDye800 and may play
some part in the increased retention time of these two agents
within the lymphatics.
From these studies, there are several significant advantages
to using cABD-IRDye800 for imaging lymphatics as com-
pared with a free dye alone. First, the cABD peptide conjugate
is uniquely directed to the lymphatic system due to its high
affinity for albumin thereby enhancing vascular retention, as
opposed to a free dye which may have a more transient
interaction or be small enough to be taken up into the blood
vasculature. Second, by conjugation to the bright near-infrared
dye, IRDye800, the imaging agent gains a brighter fluorescent
intensity, enhanced optical properties, and long term stability
in solution—all necessary for imaging key structures of the
lymphatics. In support of our selection of this fluorophore
conjugate, a previous study [56]s h o w e dt h a ti nc o m p a r i s o nt o
several other NIR fluorophores including ICG, an IRDye800
conjugate of albumin had the best outcome with respect to
physical properties, uptake and retention, fluorescence signal
and reproducibility in sentinel lymph node mapping. Our
albumin-binding domain conjugate has these favorable proper-
ties without direct conjugation at undefined sites to a bulky
albumin molecule. Third, the peptide and dye are both well
characterized, the conjugate is relatively small, readily synthe-
sized and has a quantifiable 1:1 conjugation chemistry, all of
which significantly enhance its ability to be used clinically.
Subsequent comparative murine imaging studies con-
firmed that cABD-IRDye800 shows uptake and retention in
the lymphatics, as well as high sensitivity imaging at lower
concentrations than ICG. These results again highlight the
superior optical properties of the conjugate. The ability to
use a brighter NIR fluorophore for imaging allows for the
delivery of microdose quantities of the imaging agent, which
not only reduces the possibility for any adverse reactions but
also reduces the stringency of FDA criteria in subsequent
clinical studies, thus allowing more rapid advancement of
the imaging agent to the clinic. As we intend to employ NIR
fluorophores for clinical use, it is also important that the
fluorophore be able to remain in the lymphatics for at least
1 h during the patient imaging session, which was reflected
in the time points chosen for the clearance study. Our
clearance study indicated that cABD-IRDye800 and ICG
were both retained in the lymph node longer than IRDye800
as determined by the comparatively higher total fluorescence
in the lymph node. IRDye800 (as a free dye), was able to
rapidly enter the lymphatics, but also appeared to clear very
rapidly from the inguinal lymph node and had less than 30%
of maximum fluorescence remaining at 50 min. The more
rapid clearance of IRDye800 may be attributed to the fact
that unlike ICG, which associates with albumin and serum
proteins [58] that may aid in lymphatic retention, IRDye800
may have a more transient or weaker association with MSA,
and may not bind human serum proteins at a detectable
level. This result is substantiated by the similar lymph node
clearance behavior of ICG and cABD-IRDye800, which
differed from that of IRDye800 alone. Thus, IRDye800 may
not reflect physiological protein movement in the lymphatics
as do ICG and cABD-IRDye800 and may clear too rapidly
to be useful. In particular, when imaging lymphedema
subjects with NIR fluorescence, it may not be warranted to
intradermally inject additional fluid volume or protein into
fibrotic tissue; therefore, retention of the initial microdose
over the duration of the imaging session is important.
Several fluorophores have been directly conjugated onto
large proteins or molecules such as albumin, polyethylene
glycol or hyaluronan to achieve this purpose; however, the
large size of these conjugates as well as potential issues with
chemistry, manufacturing and control of a large molecule,
may limit their clinical applicability. As a consequence, we
seek to intradermally administer the small, labeled cABD
peptide for in situ binding of serum protein and subsequent
lymphatic transit, in order to enable a diagnostic measure of
protein movement. In addition, safety and toxicity studies
with IRDye800 show a favorable toxicity profile [51], and
studies of similar ABD peptides in murine models also suggest
safety and efficacy [40], thus we expect future studies will
confirm similar outcomes for the conjugate. We anticipate this
technology will be useful in addressing the cause of patient
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changes in the vasculature over time. In addition, Kwon and
Sevick-Muraca [59] used ICG in preclinical animal models of
cancer metastasis to demonstrate progressive changes in
lymphatic vascular structure and transport function with
advancing disease. A brighter, cABD-based agent may also
be useful to better image tumor lymphangiogenesis in cancer
patients. Since several emerging therapeutics against tumor
lymphangiogenesis are under development, a more effective
agentcouldbeusedtostratifypatientswhocouldbecandidates
for anti-lymphangiogenesis therapy as well as provide a metric
to evaluate therapeutic response.
Conclusions
Based upon our collective results, cABD-IRDye800 appears to
be a favorable imaging agent for lymphatic imaging studies.
cABD-IRDye800 provides a unique opportunity to noninva-
sively image the lymphatics and to enhance our understanding
of the underlying pathology of lymphatic disease for improved
patient diagnosis, monitoring, and treatment. The ability to
translate our imaging agent, and other subsequent vascular
imaging agents into the clinic is of utmost importance as it has
significant implications for improving disease management
and outcome in a patient population in which there is very
limited knowledge of disease pathogenesis and few treatment
options. Taken together, our peptide conjugate and non-
invasive NIR imaging technology have the ability to be an
effective tool to begin to address the challenges of diagnosing
and treating lymphatic disease. Elucidating the changes that
occur in lymphatic disease will help us to further understand
the complex interplay that occurs between the lymphatics,
blood vasculature, and other organ systems invascular disease,
and may lead to future discoveries in related metabolic
disorders such as diabetes, obesity, and cancer.
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